{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:10:54Z","timestamp":1774271454916,"version":"3.50.1"},"reference-count":16,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"DOI":"10.31744\/einstein_journal\/2026suppl_2ed0001","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:19:04Z","timestamp":1774268344000},"source":"Crossref","is-referenced-by-count":0,"title":["Epidermolysis bullosa and global challenges in translational research for rare diseases"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-8026","authenticated-orcid":false,"given":"Priscila Keiko Matsumoto","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8935-1190","authenticated-orcid":false,"given":"Laurent Ketlen Le\u00e3o","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9972-152X","authenticated-orcid":false,"given":"Mel Dominici","family":"Sanfins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"6","key":"key20260323121856_B1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","article-title":"The classification of inherited epidermolysis bullosa: report of the Third International Consensus Meeting on Diagnosis and Classification of EB","volume":"58","author":"Fine","year":"2008","unstructured":"Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa: report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931-50.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"key20260323121856_B2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-5-12","article-title":"Inherited epidermolysis bullosa","volume":"5","author":"Fine","year":"2010","unstructured":"Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5(1):12.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"key20260323121856_B3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614-27.","journal-title":"Br J Dermatol"},{"issue":"2","key":"key20260323121856_B4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006","volume":"60","author":"Fine","year":"2009","unstructured":"Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol. 2009;60(2):203-11.","journal-title":"J Am Acad Dermatol"},{"key":"key20260323121856_B5","first-page":"286","article-title":"Fibrosis in recessive dystrophic epidermolysis bullosa: mechanisms and therapeutic perspectives","volume":"68-69","author":"Titeux","year":"2018","unstructured":"Titeux M, Pendaries V, Hovnanian A. Fibrosis in recessive dystrophic epidermolysis bullosa: mechanisms and therapeutic perspectives. Matrix Biol. 2018;68-69:286-300.","journal-title":"Matrix Biol"},{"issue":"5","key":"key20260323121856_B6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jid.2017.12.016","article-title":"Progress in epidermolysis bullosa research: toward treatment and cure","volume":"138","author":"Uitto","year":"2018","unstructured":"Uitto J, Bruckner-Tuderman L, McGrath JA, Riedl R, Robinson C. Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol. 2018;138(5):1010-6.","journal-title":"J Invest Dermatol"},{"issue":"7680","key":"key20260323121856_B7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327-32.","journal-title":"Nature"},{"issue":"3","key":"key20260323121856_B8","first-page":"147","article-title":"RNA-based therapies for inherited skin disorders","volume":"101","author":"Hsu","year":"2021","unstructured":"Hsu CK, Wang SP, Lee JY. RNA-based therapies for inherited skin disorders. J Dermatol Sci. 2021;101(3):147-55.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"key20260323121856_B9","first-page":"609","article-title":"Gene editing for epidermolysis bullosa: advances and challenges","volume":"186","author":"March","year":"2022","unstructured":"March OP, Kocher T, Koller U. Gene editing for epidermolysis bullosa: advances and challenges. Br J Dermatol. 2022;186(4):609-20.","journal-title":"Br J Dermatol"},{"issue":"4","key":"key20260323121856_B10","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.3390\/ijms25042243","article-title":"Emerging Gene Therapeutics for Epidermolysis Bullosa under Development","volume":"25","author":"Bischof","year":"2024","unstructured":"Bischof J, Hierl M, Koller U. Emerging Gene Therapeutics for Epidermolysis Bullosa under Development. Int J Mol Sci. 2024;25(4):2243. Review.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"key20260323121856_B11","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of epidermolysis bullosa and future directions: a review","volume":"14","author":"Danescu","year":"2024","unstructured":"Danescu S, Negrutiu M, Has C. Treatment of epidermolysis bullosa and future directions: a review. Dermatol Ther (Heidelb). 2024;14(8):2059-75.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"key20260323121856_B12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/bjd\/ljaf321","article-title":"New gene therapies for dystrophic epidermolysis bullosa: progress, promise and persistent gaps","volume":"193","author":"McGrath","year":"2025","unstructured":"McGrath JA, Tolar J. New gene therapies for dystrophic epidermolysis bullosa: progress, promise and persistent gaps. Br J Dermatol. 2025;193(5):809-10.","journal-title":"Br J Dermatol"},{"key":"key20260323121856_B13","article-title":"FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa (Vyjuvek\u2122)","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration. FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa (Vyjuvek\u2122). For Immediate Release: May 19, 2023 [cited 2026 Feb 16]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa","journal-title":"For Immediate Release"},{"issue":"2","key":"key20260323121856_B14","article-title":"Emerging therapies for epidermolysis bullosa","volume":"134","author":"Marinkovich","year":"2024","unstructured":"Marinkovich MP. Emerging therapies for epidermolysis bullosa. J Clin Invest. 2024;134(2):e170123.","journal-title":"J Clin Invest"},{"key":"key20260323121856_B15","author":"Abeona Therapeutics, Inc","year":"2025","unstructured":"Abeona Therapeutics, Inc. U.S. FDA approves ZEVASKYN\u2122 (prademagene zamikeracel). Press release. April 29, 2025 [cited 2026 Feb 16]. Available from: https:\/\/investors.abeonatherapeutics.com\/press-releases\/detail\/303\/u-s-fda-approves-zevaskyn-prademagene-zamikeracel","journal-title":"U.S. FDA approves ZEVASKYN\u2122 (prademagene zamikeracel). Press release"},{"key":"key20260323121856_B16","first-page":"S6","article-title":"Global research and patient support initiatives in epidermolysis bullosa","volume":"15","author":"DEBRA International","year":"2020","unstructured":"DEBRA International. Global research and patient support initiatives in epidermolysis bullosa. Orphanet J Rare Dis. 2020;15 Suppl 2:S6.","journal-title":"Orphanet J Rare Dis"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:19:06Z","timestamp":1774268346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/epidermolysis-bullosa-and-global-challenges-in-translational-research-for-rare-diseases\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2026,3,20]]}},"alternative-id":["10.31744\/einstein_journal\/2026Suppl_2ED0001"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026suppl_2ed0001","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eED0001"}}